BioSpace News Archive

The n-Lorem Foundation announced today that the Korea Institute of Toxicology (KIT) has become the latest institute to join in support of the n-Lorem Foundation’s efforts to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases

Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.

multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide mono-therapy for maintenance when compared to observation only.

March 19, 2020 18:40 UTC U.S. Food And Drug Administration Approves Epclusa ® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection -- Pediatric approval of protease inhibitor-free, pan-genotypic, pan-fibrotic, once-daily regimen supports HCV elimination efforts by providing critical option for broad range of populations -- FOSTER CITY, Calif.--( BUSINESS WIRE )-- Gilead Sciences, Inc. (NASDAQ: GILD) announced

CPT Medical , a surgical pack and kit manufacturing firm based in Greenville, SC , is now shipping COVID-19 testing kits that are available throughout the US. With 54,000 test kits in production for allocation to hospitals, nursing homes, and physicia

Health Canada is advising Canadians that it has seized an unauthorized prescription skin lightening product that may pose serious health risks from the Danforth Variety & Fruit Market

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and twelve months ended December 31, 2019.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019 after the close of the market on Monday, March 23, 2020.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update.